Abstract: An organic light-emitting device includes: a first electrode; a second electrode facing the first electrode; an emission region between the first electrode and the second electrode and including a first emission layer and a second emission layer; and a hole blocking layer between the first emission layer and the first electrode, or between the second emission layer and the second electrode, wherein the second emission layer may be between the first emission layer and the hole blocking layer, the first emission layer may include a first host and a first light-emitting material, the second emission layer may include a second host and a second light-emitting material, and the first light-emitting material and the second light-emitting material may respectively be included in the first emission layer and the second emission layer at an identical ratio.

Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Abstract: The present disclosure relates to calixpyrrole compounds and compositions thereof. The calixpyrrole compounds are chemical groups which are located in such a manner so as to be useful for the selective extraction of specific salts. Also provided herein are compositions and methods of use thereof.

Abstract: Disclosed is a display device that is capable of being driven with low power consumption. A first thin-film transistor including a polycrystalline semiconductor layer and a second thin-film transistor including an oxide semiconductor layer are disposed in an active area, thereby reducing power consumption. At least one opening formed in a bending area is formed to have the same depth as any one of contact holes formed in the active area, thereby making it possible to form the opening and the contact holes through the same process and consequently simplifying the process of manufacturing the device. A second source electrode of the second thin-film transistor and a second gate electrode of the second thin-film transistor overlap each other with an upper interlayer insulation film interposed therebetween so as to form a first storage capacitor.

Abstract: Provided are a compound of Chemical Formula 1: and an organic light emitting device including the same.

Abstract: Disclosed are a series of photoisomeric compounds, preparation method therefor and device comprising the compounds, wherein a photoisomeric compound-graphene molecular junction device is formed by linking the photoisomeric compound to a gap of two-dimensional monolayer graphene having a nano-gap array via an amide covalent bond. When a single photoisomeric compound is bridged to the gap of the two-dimensional monolayer graphene having a nano-gap array, the devices have a reversible light-controlled switching function and a reversible electrically-controlled switching function. A molecular switch device prepared by the method can achieve a high reversibility and a good reproducibility. The number of light-controlled switching cycles can exceed 104, and the number of electrically-controlled switching cycles can reach about 105 or greater. Moreover, the above-mentioned reversible molecular switch device remains stable within a period of more than one year.

Abstract: The present disclosure relates to novel, scalable methods of making substituted tricyclic compounds that are useful to treat and/or prevent HBV and/or HBV-HDV infection and related conditions in a subject.

Abstract: The invention relates to novel compounds useful as ligands of actinides and which meet general formula (I) hereinafter: where: R1 and R2=H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; R3, R4, R5 and R6=H; a C1 to C12 hydrocarbon group; a monocyclic aryl or aryl-(C1 to C6)alkyl group; a —NR7R8 or —NR7COR8 group where R7=H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group, while R8=a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; an —OR9 or —SR9 group where R9=a C1 to C12 hydrocarbon group, a monocyclic C6 aryl or aryl-(C1 to C6)alkyl group. A further subject of the invention is a method for synthesizing these compounds and the uses thereof.

Abstract: A novel organic compound is provided. Alternatively, an organic compound that can be used as an electron-transport material of a light-emitting element is provided. An organic compound in which heteroaromatic groups each including two pyridine rings are bonded to the 2- and 8-positions of dibenzofuran is provided. The organic compound is an organic compound that can be used as an electron-transport material of a light-emitting element.

Abstract: A method of inhibiting cancer cell growth is provided. In some versions, the method includes exposing lung cancer cells or glioma cells to 2,9-di-sec-butyl-1,10-phenanthroline (SBP) or derivatives of SBP in an amount effective to inhibit glioma cell growth. Also, a method of treating a lung cancer or a glioma tumor in a subject in need of such treatment is provided. The method includes administering SBP or derivatives of SBP to the subject in an amount effective to treat the lung cancer or glioma tumor. For either method, the method can further include exposing or administering pseudo five coordinate gold(III) complexes of SBP derivatives.

Abstract: An anthracene-based compound is represented by Formula 1 as below: wherein Ar, R1 to R3, R11 to R13, L1, L2, a1 to a3, b1, b2, n1, n2, m1, m2, o1 and o2 are as defined in the specification. An organic light-emitting device includes the anthracene-based compound.

Abstract: The present invention relates to 4H-pyrido[1,2-a]pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Abstract: Disclosed are 1,4-dihydro-naphthyridine derivatives and pharmaceutical composition and uses thereof. The 1,4-dihydro-naphthyridine derivatives are a compound capable of inhibiting acetylcholinesterase activity and preventing extracellular calcium from flowing into a cell via a calcium channel, i.e., having a dual-activity, which are of potential importance as a pharmaceutical and can be used to prepare the drugs for treating cardiovascular diseases, cerebrovascular diseases and dementia.

Abstract: A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Substituents in Formula 1 are the same as defined in the specification.

Abstract: A engineered composition and method of delivery of said composition providing effective therapy for the treatment of ulcerative colitis, and Crohn's disease.

Abstract: The present invention provides a novel organic compound having a high quantum yield and a high color purity. Provided is an organic compound represented by Formula (1) described in Claim 1. In Formula (1), R1 to R20 are each independently selected from hydrogen atoms, halogen atoms, substituted or unsubstituted alkyl groups, substituted or unsubstituted alkoxy groups, substituted or unsubstituted amino groups, substituted or unsubstituted aryl groups, substituted or unsubstituted heterocyclic groups, substituted or unsubstituted aryloxy groups, substituted or unsubstituted thiol groups, silyl groups, and cyano groups.

Abstract: The invention provides methods for substituting polyaromatic hydrocarbons or polyheterocyclic compounds with perfluoroalkyl groups. The methods can include heating a polyaromatic hydrocarbon substrate or a polyheterocyclic compound substrate in the presence of a perfluoroalkyl iodide, typically in a closed system, wherein the heating is sufficient to bring both the polyaromatic hydrocarbons or polyheterocyclic compound, and the perfluoroalkyl iodide, into the gas phase, thereby allowing the substrate to react with the perfluoroalkyl iodide in the gas phase to form polyaromatic hydrocarbons or polyheterocyclic compounds having one or more perfluoroalkyl substituents. The methods allow for the creation of versatile libraries of novel perfluoroalkyl-containing derivatives that can serve as important building blocks and active components in biomedical, electronic, and materials applications.

Abstract: An organic electroluminescence device including an anode and a cathode being opposed, wherein a first organic thin film layer and a second organic thin film layer are provided between the anode and the cathode sequentially from the anode side; the first organic thin film layer including an aromatic heterocyclic derivative A represented by the following formula (1-1) and a phosphorescent emitting material; and the second organic thin film layer including an aromatic heterocyclic derivative B represented by the following formula (2-1):

Abstract: Disclosed is an organic electroluminescent device (organic EL device) that is improved in the luminous efficiency, fully secured of the driving stability, and of a simple structure and also disclosed is a compound for organic EL device useful for the said device. The compound for organic EL device is, for example, an indolocarbazole derivative represented by the following general formula (3). The organic EL device comprises a light-emitting layer disposed between an anode and a cathode piled one upon another on a substrate and the said light-emitting layer comprises a phosphorescent dopant and the aforementioned indolocarbazole derivative as a host material. In general formula (3), L is an aromatic heterocyclic group of a fused-ring structure with a valence of (n+1), Ar1 to Ar3 each is an alkyl group, an aralkyl group, or a substituted or unsubstituted aromatic hydrocarbon or aromatic heterocyclic group, and n is an integer of 0-5.

Abstract: The present invention describes copolymers containing indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the interlayer, emission and/or charge-transport layer of electroluminescent devices, and the monomers which are necessary for the preparation of the copolymers. The invention furthermore relates to a process for the preparation of the copolymers according to the invention, and to electronic devices comprising same.

Abstract: A condensed-cyclic compound and an organic light-emitting diode including the condensed-cyclic compound.

Abstract: A compound is represented by a formula (1) below. In the formula (1), X1 to X8 each independently represent a carbon atom to be bonded to a group represented by the following formula (20), CRX or a nitrogen atom. At least one of X1 to X8 is a carbon atom to be bonded to the group represented by the following formula (2). RX is each independently a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 30 carbon atoms, or the like.

Abstract: Compounds and uses of the compounds are provided. The compounds can be used as Fe(II) sequestering compounds. For example, these compounds can be used to sequester Fe(II) in cells, organs, vasculature, or tissues. Also, provided are compositions and methods of using the them for sequestering Fe(II) in an individual. The compounds can be used as MRI paraCEST contrast agents.

Abstract: A pyrene compound and an organic light emitting diode device including the same are disclosed. The organic light emitting diode device includes at least two stacks provided between a first electrode and a second electrode, and a charge generation layer provided between the stacks and including an N type charge generation layer and a P type charge generation layer, wherein the N type charge generation layer is made of the pyrene compound.

Abstract: A method of staining a poly(amino acid) by contacting a poly(amino acid) with an overall neutral or overall cationic complex of at least one of transition metal ion, and a plurality of donor ligands each of which is fully coordinated to the transition metal ion and is either a nitrogen donor ligand or a cyclometalated donor ligand, such that at least one of the donor ligands is a cyclometalated donor ligand. Nitrogen donor ligands will contain heteroaryl ring systems having from 10 to 40 ring atoms, wherein each nitrogen donor ligand is substituted with from 0 to 4 R1 groups. Cyclometalated donor ligands will likewise contain heteroaryl ring systems having from 10 to 40 ring atoms, such that at least one ring atom is N, wherein each cyclometalated donor ligand is substituted with from 0 to 4 R1 groups. R1, R2, R3 and R4 groups are defined herein.

Abstract: The present invention provides compounds of formula (I) wherein A1, A2, R1, D1, D2, Y3 and X are as defined in the claims. The invention further relates to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

Abstract: The present invention provides a novel compound having a phenanthroline structure represented by formula (I) or a salt thereof:

Abstract: The invention relates to novel compounds useful as ligands of actinides and which meet general formula (I) hereinafter: where: R1 and R2?H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; R3, R4, R5 and R6?H; a C1 to C12 hydrocarbon group; a monocyclic aryl or aryl-(C1 to C6)alkyl group; a —NR7R8 or —NR7COR8 group where R7?H, a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group, whilst R8=a C1 to C12 hydrocarbon group, a monocyclic aryl or aryl-(C1 to C6)alkyl group; an —OR9 or —SR9 group where R9=a C1 to C12 hydrocarbon group, a monocyclic C6 aryl or aryl-(C1 to C6)alkyl group. A further subject of the invention is a method for synthesizing these compounds and the uses thereof.

Abstract: A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Substituents in Formula 1 are the same as defined in the specification.

Abstract: Provided is an organic light-emitting device having an optical output with high luminance and high color purity with extremely high efficiency. The organic light-emitting device includes an organic layer between the anode and the cathode, in which one of the anode and the cathode is a transparent electrode or a semi-transparent electrode and at least one layer of the organic layer contains at least one kind of indenopyrene compound having a specific structure.

Abstract: Embodiments of the present invention are directed to a condensed-cyclic compound represented by Formula 1, and to an organic light-emitting diode including the same.

Abstract: A compound for an organic photoelectric device, an organic photoelectric device including the same, and a display device including the same the compound being represented by the following Chemical Formula 1:

Abstract: To provide a novel chrysene compound and an organic light-emitting device having high emission efficiency and excellent driving durability, provided is a novel triaryl-substituted chrysene compound represented by the general formula [1]: wherein Ar1 to Ar3 each represent a substituent selected from the group consisting of a substituted or unsubstituted naphthyl group, a substituted or unsubstituted phenanthryl group, and a substituted or unsubstituted fluorenyl group.

Abstract: Provided are a process for preparing an N ortho acyl substituted nitrogen-containing heterocyclic compound and an aminal iron (II) complex thereof, and the use of the complexes obtained by the process in an olefin oligomerization catalyst. The N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is for example 2-acyl-1,10-phenanthroline or 2,6-diacetyl pyridine as shown in formula b, and the N ortho acyl substituted nitrogen-containing heterocyclic compound in the present invention is produced by a reaction of a precursor thereof in a substituted or unsubstituted nitrobenzene. Preferably the precursor shown in formula I in the present invention is produced by 1,10-phenanthroline reacting with trialkyl aluminum, or a halogenoalkyl aluminum RnAlXm, or a substituted or unsubstituted benzyl lithium 2Li, followed by hydrolysis.

Abstract: Disclosed is a compound suitable for use as a fluorescent probe for the detection of uranium. The compound enables the qualitative and quantitative analysis of uranium present in waste samples using less expensive apparatuses. The compound of the present invention has the structure shown by the following formula.

Abstract: An organic EL device is provided that includes an emitting layer provided between an anode and a cathode. The emitting layer contains a diaminopyrene derivative represented by the following formula (1) as an emitting material for the organic EL device. The diaminopyrene derivative emits light with electrical energy.

Abstract: A compound represented by the following formula (1), wherein L is a single bond or a divalent group, and is bonded at any one of the 6th, 8th and the 9th positions indicated by * of 1,10-phenanthroline; Rg is a substituted or unsubstituted benzene ring or a substituted or unsubstituted naphthalene ring; and X is an oxygen atom or N—R4.

Abstract: This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.

Abstract: A heterocyclic compound of formula 1 and an organic light-emitting device including an organic layer containing the heterocyclic compound. The heterocyclic compound of Formula 1 may be suitable as a material for an emission layer, an electron transport layer or an electron injection layer of an organic light-emitting device. Due to the inclusion of the heterocylic group in its molecular structure, the heterocyclic compound of Formula 1 may have a high glass transition temperature (Tg) or a high melting point, and may prevent crystallization. An organic light-emitting device manufactured using the heterocyclic compound of Formula 1, which has a symmetrical structure in which a chrysene group and an indole group are fused, has excellent durability when stored or operated.

Abstract: The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: Copper plating baths containing a leveling agent that is a reaction product of one or more of certain pyridine compounds with one or more epoxide-containing compounds, that deposit copper on the surface of a conductive layer are provided. Such plating baths deposit a copper layer that is substantially planar on a substrate surface across a range of electrolyte concentrations. Methods of depositing copper layers using such copper plating baths are also disclosed.

Abstract: The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.

Abstract: The present invention provides a quinolone compound that inhibits the chronic progression of Parkinson's disease or protects dopamine neurons from disease etiology, thereby suppressing the progression of neurological dysfunction, so as to prolong the period of time until L-dopa is administered while also improving neuronal function; the quinolone compound of the invention is represented by Formula (1): wherein: R1 represents hydrogen or the like; R2 represents hydrogen or the like; R3 represents substituted or unsubstituted phenyl or the like; R4 represents halogen or the like; R5 represents hydrogen or the like; R6 represents hydrogen or the like; and R7 represents hydrogen or the like.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including an organic layer that includes the following heterocyclic compound: wherein R1 to R13 are each independently a hydrogen atom, a heavy hydrogen atom, a substituted or unsubstituted C1-C60 alkyl group, a substituted or unsubstituted C2-C60 alkenyl group, a substituted or unsubstituted C2-C60 alkynyl group, a substituted or unsubstituted C3-C60 cycloalkyl group, a substituted or unsubstituted C1-C60 alkoxy group, a substituted or unsubstituted C5-C60 aryloxy group, a substituted or unsubstituted C5-C60 arylthio group, a substituted or unsubstituted C5-C60 aryl group, an amino group substituted with a C5-C60 aryl group or a C3-C60 heteroaryl group, a substituted or unsubstituted C3-C60 heteroaryl group, a substituted or unsubstituted C6-C60 condensed polycyclic group, a halogen atom, a cyano group, a nitro group, a hydroxy group, or a carboxy group.

Abstract: The present invention provides moieties that bind to the asymmetric contact interface of a receptor tyrosine kinase (RTK), wherein the moieties inhibit ligand induced trans autophosphorylation of the RTK. The present invention also provides methods of treating or preventing an RTK-associated disease and methods for identifying moieties that bind to an asymmetric contact interface of an RTK.

Abstract: There is provided an organic electronic device having an anode, a hole injection layer, a photoactive layer, an electron transport layer, and a cathode. At least one of the photoactive layer and the electron transport layer includes a compound having Formula I where: R1 is the same or different and can be phenyl, biphenyl, naphthyl, naphthylphenyl, triphenylamino, or carbazolylphenyl; and one of the following conditions is met: (i) R2=R3 and is H, phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, or carbazolylphenyl; or (ii) R2 is H or phenyl; and R3 is phenyl, biphenyl, naphthyl, naphthylphenyl, arylanthracenyl, phenanthryl, triphenylamino, and carbazolylphenyl; When both R1 are phenyl, R2 and R3 can be 2-naphthyl, naphthylphenyl, arylanthracenyl, 9-phenanthryl, triphenylamino, or m-carbazolylphenyl.

Abstract: To provide nitrogen-containing aromatic compounds with excellent oxygen reduction activity, metal complexes containing them, and catalysts and electrodes employing the same, the present invention provides an aromatic compound satisfying the following conditions (a) and (b): (a) It has 2 or more structures surrounded by at least 4 coordinatable nitrogen atoms (which structures may be the same or different), (b) At least one of the nitrogen atoms composing the structure is a nitrogen atom in a 6-membered nitrogen-containing heterocyclic ring.

Abstract: The present invention provides a novel compound having a phenanthroline structure represented by formula (I) or a salt thereof:

Abstract: The sponges were collected from a variety of locations in the Florida Keys and separated based on morphology and color. The samples were identified as three species, two of which are well known: V. rigida (Esper, 1794) (order Verongida, family Aplysinidae) and S. aurea (Hyatt, 1875) (order Dictyoceratida, family Thorectidae), and a third S. cerebriformis (Duchassaing & Michelotti, 1864), is less common and separated based on subtle differences of morphology and coloration, from the other two species. Several compounds were isolated and were evaluated in established animal models predictive of neurological related drug function, namely, the rodent FST and the chick anxiety-depression model.